EKF Diagnostics Holdings PLC New orders for COVID-19 sample collection kits

TIDMEKF

EKF Diagnostics Holdings PLC

22 October 2020

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

New supply orders for COVID-19 sample collection kits

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has received initial orders for PrimeStore MTM COVID-19 sample collection devices from two new customers, the Health Service Executive ("HSE"), Ireland and a national health body in England. These orders will be fulfilled from EKF's production facilities in Penarth, South Wales and Barleben, Germany.

These orders will contribute to the expected strong Q4 performance and the Company intends to provide a further update on trading in early November.

 
     EKF Diagnostics Holdings plc                                        www.ekfdiagnostics.com 
     Christopher Mills, Non-executive Chairman                        Tel: [phone] 
     Julian Baines, CEO 
     Richard Evans, FD & COO 
 
     N+1 Singer                                                              Tel: [phone] 
     Aubrey Powell / George Tzimas (Corporate 
      Finance) 
      Tom Salvesen (Corporate Broking) 
 
     Walbrook PR Limited                        Tel: [phone] or [e-mail] 
     Paul McManus / Lianne Cawthorne                   Mob: [phone] 
                                                                                        391 303 
 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

About PrimeStore MTM

The PrimeStore MTM sample collection device, deactivates viruses, bacteria, fungi and mycobacterium tuberculosis allowing safe sample handling and transport, greatly reducing risk of infection. The device was invented by Longhorn Vaccines and Diagnostics LLC ("Longhorn") in the US, in 2006 in preparation for a worldwide pandemic and is designed to de-activate pathogen rapidly and stabilise the RNA for up to four weeks with no requirement for cold storage. In the case of COVID-19, by deactivating the virus testing can now take place outside of containment facilities opening up capacity in more testing laboratories. With the flu season approaching, the PrimeStore MTM can also safely collect flu and COVID-19 samples in the same collection kit.

PrimeStore MTM was successfully evaluated for effective SARS-CoV-2 inactivation in a study published by PHE. The study showed that of the few transport reagents, from the 23 tested, where no residual virus was detectable, PrimeStore MTM is the only commercially available CE-marked and FDA cleared transport media. EKF is a contract manufacturer for the PrimeStore MTM sample collection device.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABRBDGGXDDGGB

(END) Dow Jones Newswires

October 22, 2020 02:00 ET (06:00 GMT)